205 related articles for article (PubMed ID: 32899203)
1. Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma.
Rahimi Koshkaki H; Minasi S; Ugolini A; Trevisi G; Napoletano C; Zizzari IG; Gessi M; Giangaspero F; Mangiola A; Nuti M; Buttarelli FR; Rughetti A
J Pers Med; 2020 Sep; 10(3):. PubMed ID: 32899203
[TBL] [Abstract][Full Text] [Related]
2. Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma.
Tamura R; Ohara K; Sasaki H; Morimoto Y; Kosugi K; Yoshida K; Toda M
World Neurosurg; 2018 Dec; 120():e601-e610. PubMed ID: 30165233
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy.
Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W
Elife; 2020 Sep; 9():. PubMed ID: 32909947
[TBL] [Abstract][Full Text] [Related]
4. Identification of a unique tumor cell subset employing myeloid transcriptional circuits to create an immunomodulatory microenvironment in glioblastoma.
Yang K; Shi Y; Luo M; Mao M; Zhang X; Chen C; Liu Y; He Z; Liu Q; Wang W; Luo C; Yin W; Wang C; Niu Q; Zeng H; Bian XW; Ping YF
Oncoimmunology; 2022; 11(1):2030020. PubMed ID: 35096487
[TBL] [Abstract][Full Text] [Related]
5. TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM.
Hung AL; Maxwell R; Theodros D; Belcaid Z; Mathios D; Luksik AS; Kim E; Wu A; Xia Y; Garzon-Muvdi T; Jackson C; Ye X; Tyler B; Selby M; Korman A; Barnhart B; Park SM; Youn JI; Chowdhury T; Park CK; Brem H; Pardoll DM; Lim M
Oncoimmunology; 2018; 7(8):e1466769. PubMed ID: 30221069
[TBL] [Abstract][Full Text] [Related]
6. Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases.
He Y; Han Y; Fan AH; Li D; Wang B; Ji K; Wang X; Zhao X; Lu Y
J Transl Med; 2022 Oct; 20(1):454. PubMed ID: 36195882
[TBL] [Abstract][Full Text] [Related]
7. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
8. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
9. Immunosuppressive tumor microenvironment in occupational cholangiocarcinoma: Supportive evidence for the efficacy of immune checkpoint inhibitor therapy.
Sato Y; Tanaka S; Kinoshita M; Takemura S; Shinkawa H; Kokudo T; Hasegawa K; Tanaka H; Yoshimoto H; Mori A; Yamamura M; Sasaki M; Harada K; Kubo S
J Hepatobiliary Pancreat Sci; 2020 Nov; 27(11):860-869. PubMed ID: 32506715
[TBL] [Abstract][Full Text] [Related]
10. Advanced Age Increases Immunosuppression in the Brain and Decreases Immunotherapeutic Efficacy in Subjects with Glioblastoma.
Ladomersky E; Zhai L; Lauing KL; Bell A; Xu J; Kocherginsky M; Zhang B; Wu JD; Podojil JR; Platanias LC; Mochizuki AY; Prins RM; Kumthekar P; Raizer JJ; Dixit K; Lukas RV; Horbinski C; Wei M; Zhou C; Pawelec G; Campisi J; Grohmann U; Prendergast GC; Munn DH; Wainwright DA
Clin Cancer Res; 2020 Oct; 26(19):5232-5245. PubMed ID: 32546647
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Strategies for Overcoming Immunotherapy Resistance Mediated by Immunosuppressive Factors of the Glioblastoma Microenvironment.
Miyazaki T; Ishikawa E; Sugii N; Matsuda M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32707672
[TBL] [Abstract][Full Text] [Related]
12. Local Targeting of NAD
Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H
Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
14. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
Liu Y; Song C; Shen F; Zhang J; Song SW
PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
[TBL] [Abstract][Full Text] [Related]
15. Immune landscapes associated with different glioblastoma molecular subtypes.
Martinez-Lage M; Lynch TM; Bi Y; Cocito C; Way GP; Pal S; Haller J; Yan RE; Ziober A; Nguyen A; Kandpal M; O'Rourke DM; Greenfield JP; Greene CS; Davuluri RV; Dahmane N
Acta Neuropathol Commun; 2019 Nov; 7(1):203. PubMed ID: 31815646
[TBL] [Abstract][Full Text] [Related]
16. Identification of cytokine-predominant immunosuppressive class and prognostic risk signatures in glioma.
Tian Z; Yang Z; Jin M; Ding R; Wang Y; Chai Y; Wu J; Yang M; Zhao W
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13185-13200. PubMed ID: 37479756
[TBL] [Abstract][Full Text] [Related]
17. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma.
Zhai L; Bell A; Ladomersky E; Lauing KL; Bollu L; Nguyen B; Genet M; Kim M; Chen P; Mi X; Wu JD; Schipma MJ; Wray B; Griffiths J; Unwin RD; Clark SJ; Acharya R; Bao R; Horbinski C; Lukas RV; Schiltz GE; Wainwright DA
Clin Cancer Res; 2021 Dec; 27(23):6514-6528. PubMed ID: 34479957
[TBL] [Abstract][Full Text] [Related]
18. Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kγ inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells.
Miyazaki T; Ishikawa E; Matsuda M; Sugii N; Kohzuki H; Akutsu H; Sakamoto N; Takano S; Matsumura A
Brain Tumor Pathol; 2020 Apr; 37(2):41-49. PubMed ID: 31980975
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Associated CD163
Guo F; Feng YC; Zhao G; Zhang R; Cheng ZZ; Kong WN; Wu HL; Xu B; Lv X; Ma XM
Cancer Manag Res; 2020; 12():5831-5843. PubMed ID: 32765086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
